Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The ACTIV-2 study aims to determine whether neutralizing antibodies reduce the duration of COVID-19 symptoms.
Vaccines that stimulate immune responses against cancer using the mRNA technology may be fast-acting and cheap to make.
Bamlanivimab did not speed clinical improvement or reduce the time to hospital discharge or sustained recovery.
Two Phase III clinical trials are evaluating monoclonal antibodies for people hospitalized with moderate COVID-19.
The anti-inflammatory and antiviral drug combination reduced time to recovery for people hospitalized with COVID-19.
In Los Angeles County, daily new COVID cases, deaths and hospitalizations have soared beyond their previous highs.
Lies infected America in 2020. The very worst were not just damaging, but deadly.
Agency grants emergency authorization for antibody cocktail given to President Trump.
Arthritis drug Olumiant (baricitinib) can be used in combination with remdesivir.
Recovery and death rates were similar in people treated with the anti-malaria drug or a placebo.
Bamlanivimab is now authorized for nonhospitalized people at high risk for progressing to severe COVID-19.
None of the four drugs tested in the WHO’s Solidarity trial reduced mortality or duration of hospitalization.
Black and Latino cancer patients have higher rates of coronavirus infection and hospitalization but are less likely to use telehealth.
The HIV protease inhibitor combination did not speed recovery or reduce the risk of death in a large study.
The treatment reduced coronavirus levels and sped up recovery in a clinical trial.
The panel’s goal is to ensure that all coronavirus therapeutics approved by the government are safe and effective for African Americans.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.